Ionis Pharmaceuticals IncNASDAQ:IONS
- LAST PRICE40.4300
- TODAY'S CHANGE (%)0.7400 (1.8644%)
- Bid / Lots40.3900/ 2
- Ask / Lots40.4300/ 1
- Open / Previous Close40.3100 / 39.6900
- Day Range
- 52 Week Range
- Volume205,500
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IONS |
|---|---|---|
| 09:32 ET | 10799 | 40.36 |
| 09:34 ET | 1824 | 40.36 |
| 09:36 ET | 300 | 40.145 |
| 09:38 ET | 100 | 40.08 |
| 09:41 ET | 350 | 40.08 |
| 09:43 ET | 515 | 40.01 |
| 09:45 ET | 10214 | 40.095 |
| 09:48 ET | 2563 | 40.055 |
| 09:50 ET | 1826 | 40.11 |
| 09:52 ET | 1082 | 40.11 |
| 09:54 ET | 26134 | 40.14 |
| 09:56 ET | 8467 | 40.22 |
| 09:57 ET | 500 | 40.3 |
| 09:59 ET | 1600 | 40.3 |
| 10:01 ET | 2000 | 40.29 |
| 10:03 ET | 600 | 40.355 |
| 10:06 ET | 100 | 40.335 |
| 10:08 ET | 956 | 40.35 |
| 10:10 ET | 3173 | 40.31 |
| 10:12 ET | 1844 | 40.24 |
| 10:14 ET | 4550 | 40.205 |
| 10:15 ET | 12207 | 40.28 |
| 10:17 ET | 8725 | 40.24 |
| 10:19 ET | 4558 | 40.25 |
| 10:21 ET | 2167 | 40.24 |
| 10:26 ET | 1400 | 40.21 |
| 10:28 ET | 2293 | 40.2 |
| 10:30 ET | 40131 | 40.29 |
| 10:32 ET | 950 | 40.31 |
| 10:33 ET | 329 | 40.33 |
| 10:35 ET | 2023 | 40.34 |
| 10:37 ET | 1100 | 40.43 |
| 10:39 ET | 3278 | 40.47 |
| 10:42 ET | 2000 | 40.415 |
| 10:44 ET | 200 | 40.43 |
Jun 3, 2024
DJ Ionis Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham, from 5:39AM ET on Monday Jun 03, 2024 by Dow Jones
5:39AM ET on Monday Jun 03, 2024 by Dow Jones
May 31, 2024
May 28, 2024
Ionis to hold donidalorsen Phase 3 data webcast, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
May 23, 2024
May 16, 2024
DJ Ionis to Fly Solo on Angelman Syndrome Drug -- Market Talk, from 11:52AM ET on Thursday May 16, 2024 by Dow Jones
11:52AM ET on Thursday May 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ionis Pharmaceuticals Inc | 5.8B | -15.1x | --- |
Halozyme Therapeutics Inc | 6.5B | 20.8x | --- |
Apellis Pharmaceuticals Inc | 5.1B | -12.4x | --- |
CRISPR Therapeutics AG | 5.1B | -24.4x | --- |
Guardant Health Inc | 3.7B | -7.9x | --- |
Intra-Cellular Therapies Inc | 7.3B | -60.1x | --- |
Company Information
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Contact Information
- Headquarters
- 2855 Gazelle CourtCARLSBAD, CA, United States 92010
- Phone
- 760-931-9200
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Joseph Loscalzo
- Chief Executive Officer, Director
- Brett Monia
- Chief Financial Officer, Executive Vice President - Finance
- Elizabeth Hougen
- Executive Vice President, Chief Scientific Officer
- C. Frank Bennett
- Executive Vice President, Chief Business Officer
- Joseph Baroldi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.8B |
|---|---|
Revenue (TTM) | $776.6M |
Shares Outstanding | 146.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.36 |
EPS | $-2.67 |
Book Value | $2.68 |
P/E Ratio | -15.1x |
Price/Sales (TTM) | 7.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -48.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
